Effect and impact of alendronate on arteriosclerosis in postmenopausal patients with diabetic osteoporosis
MA Dan-jun
WANG Zheng
REN Hongli
SUN Xiujuan
ZHOU Jingrong
Abstract:Objective To investigate the effect of alendronate sodium in treatment of postmenopausal diabetic osteo-porosis( DOP) and effect on atherosclerosis( AS) .Methods 86 cases of postmenopausal DOP patients were randomly divided into treatment group and control group with 43 cases in each group.All patients were given Caltrate D oral based on quantified diet, exercise therapy and blood sugar control, the treatment group was treated with Allen alendronate 70 mg/week for 6 months.Bone mineral density (BMD), bone turnover markers and area of plaque and intima-media thickness (IMT) changes between the 2 groups were observed.Results After treatment, BMD and bone turnover markers were significantly improved in the treatment group ( P <0.05), L2~4, the femoral neck, Wards’ triangle BMD and parathyroid hormone (PTH), type I carboxy terminal peptide sequence ( beta special CTX) in the treatment group were significantly higher than that of the control group ( t =3.91,2.62, 3.70, 2.68, 3.17, P <0.05);while all indexes in the control group were not significant improve-ment ( P >0.05).After the treatment, the treatment group’ s carotid plaque area reduced obviously, IMT was obviously thinning ( t =2.64, 4.61, P <0.05);and after treatment, they were superior to the control group ( t =3.01, 2.79, P <0.05);while in the control group, there were no significant improvement ( P >0.05).Plaque area were negative correlated with lumbar L2~4 BMD ( r =-0.578, P <0.05), IMT was negatively correlated with Wards triangle and Troch BMD (r =-0.591, -0.541, P <0.05).Conclusion Postmenopausal patients with type 2 diabetes are at high risk of postmenopausal diabetic osteoprosis, Allen phosphonic acid sodium in treatment of postmenopausal DOP is safe and effective, can significantly increase the bone density, decrease bone conversion level, and has a certain role in the prevention and treatment of atheroscle-rosis.
Keywords:AlendronateDiabetestype 2OsteoporosisMenopauseAtherosclerosis
Publication Date:2015-01-01
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:4( 705-707,711 )
